Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BNTC 
Benitec Biopharma Ltd ADR (BNTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: BNTC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 42.05% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 215.39M USD | Price to earnings Ratio - | 1Y Target Price 24 |
Price to earnings Ratio - | 1Y Target Price 24 | ||
Volume (30-day avg) 46568 | Beta 0.88 | 52 Weeks Range 4.75 - 16.90 | Updated Date 03/30/2025 |
52 Weeks Range 4.75 - 16.90 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.51 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -49.6% | Return on Equity (TTM) -91.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 264244799 | Price to Sales(TTM) 2770.13 |
Enterprise Value 264244799 | Price to Sales(TTM) 2770.13 | ||
Enterprise Value to Revenue 10457.68 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 19815000 | Shares Floating 3878280 |
Shares Outstanding 19815000 | Shares Floating 3878280 | ||
Percent Insiders 4.39 | Percent Institutions 46.12 |
Analyst Ratings
Rating 4.57 | Target Price 24 | Buy 3 | Strong Buy 4 |
Buy 3 | Strong Buy 4 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Benitec Biopharma Ltd ADR
Company Overview
History and Background
Benitec Biopharma Ltd ADR was founded in 1997 in Australia, focusing on RNAi-based therapeutics. It has undergone restructuring and strategic shifts, including relocation to the US, and focusing on ocular gene therapy.
Core Business Areas
- Ocular Gene Therapy: Development of gene therapies for ocular diseases using DNA-directed RNA interference (ddRNAi) technology. Lead product candidate is OCB-203 for ocular surface disease. Previously had Oncology focus.
Leadership and Structure
CEO: Carla S. Tracewski. Organizational structure is a typical biotech company with research, development, and clinical operations divisions.
Top Products and Market Share
Key Offerings
- OCB-203: A DNA-directed RNA interference (ddRNAi) based gene therapy targeting ocular surface disease including ocular allergy. Currently in pre-clinical development. Competitors include companies developing treatments for allergic conjunctivitis and dry eye, such as Novartis (NOVN), Alcon (ALC), and others focusing on topical treatments.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, especially in ophthalmology. Increasing prevalence of ocular diseases and advancements in gene delivery technologies drive market expansion.
Positioning
Benitec is a niche player focused on ddRNAi technology for ocular diseases. Its competitive advantage lies in the specificity and potential for durable therapeutic effects of its approach.
Total Addressable Market (TAM)
The global ocular surface disease treatment market is estimated to be around $6.6 billion in 2024 and expected to grow. Benitec's positioning aims to capture a share of this market through novel gene therapies.
Upturn SWOT Analysis
Strengths
- Proprietary ddRNAi technology
- Focus on ocular gene therapy (growing area)
- Potential for durable therapeutic effects
Weaknesses
- Limited financial resources
- Early stage of development
- Reliance on a single technology platform
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new ocular disease targets
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Dilution Risk.
Competitors and Market Share
Key Competitors
- NOVN
- ALC
- LLY
Competitive Landscape
Benitec is a small player compared to larger pharmaceutical companies. Its competitive advantage relies on its proprietary technology and focus on a specific disease area.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been defined by pipeline development rather than revenue generation.
Future Projections: Future growth is contingent upon successful clinical trials and potential partnerships or acquisitions.
Recent Initiatives: Focus on OCB-203 development and strategic partnerships for manufacturing and clinical trials.
Summary
Benitec Biopharma is a high-risk, high-reward biotech company focusing on ocular gene therapy. While its proprietary technology offers potential advantages, it faces significant challenges related to funding, clinical trial success, and competition from established players. Success hinges on positive clinical data and strategic partnerships to advance its pipeline.
Similar Companies
- VIRX
- CRIS
- EDIT
- FOLD
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investing in biotechnology companies involves significant risks, including the risk of losing your entire investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Benitec Biopharma Ltd ADR
Exchange NASDAQ | Headquaters Hayward, CA, United States | ||
IPO Launch date 2015-08-18 | Executive Chairman & CEO Dr. Jerel A. Banks M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://benitec.com |
Full time employees 16 | Website https://benitec.com | ||
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.